Molecular Partners
Market Cap
CHF462.0m
Last Updated
2020/05/27 04:58 UTC
Data Sources
Company Financials +
Executive Summary
Molecular Partners AG operates as a clinical-stage biopharmaceutical company.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with high growth potential.
Similar Companies
Share Price & News
How has Molecular Partners's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MOLN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-5.3%
MOLN
-2.5%
CH Biotechs
-1.2%
CH Market
1 Year Return
35.4%
MOLN
6.0%
CH Biotechs
1.3%
CH Market
Return vs Industry: MOLN exceeded the Swiss Biotechs industry which returned 4.1% over the past year.
Return vs Market: MOLN exceeded the Swiss Market which returned 1.9% over the past year.
Shareholder returns
| MOLN | Industry | Market | |
|---|---|---|---|
| 7 Day | -5.3% | -2.5% | -1.2% |
| 30 Day | -4.3% | -18.9% | -0.1% |
| 90 Day | -3.4% | 4.0% | -5.1% |
| 1 Year | 35.4%35.4% | 6.5%6.0% | 4.6%1.3% |
| 3 Year | -27.5%-27.5% | -63.9%-64.8% | 14.9%3.2% |
| 5 Year | -41.6%-41.6% | 59.8%54.5% | 24.8%4.0% |
Price Volatility Vs. Market
How volatile is Molecular Partners's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Can We See Significant Insider Ownership On The Molecular Partners AG (VTX:MOLN) Share Register?2 months ago | Simply Wall St
Should You Be Pleased About The CEO Pay At Molecular Partners AG's (VTX:MOLN)3 months ago | Simply Wall St
When Can We Expect A Profit From Molecular Partners AG (VTX:MOLN)?Valuation
Is Molecular Partners undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MOLN (CHF21.25) is trading below our estimate of fair value (CHF53.96)
Significantly Below Fair Value: MOLN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MOLN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MOLN is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MOLN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MOLN is overvalued based on its PB Ratio (8.5x) compared to the CH Biotechs industry average (1.7x).
Next Steps
Future Growth
How is Molecular Partners forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
34.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MOLN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.2%).
Earnings vs Market: MOLN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MOLN's is expected to become profitable in the next 3 years.
Revenue vs Market: MOLN's revenue (20.5% per year) is forecast to grow faster than the Swiss market (2.4% per year).
High Growth Revenue: MOLN's revenue (20.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MOLN's Return on Equity is forecast to be low in 3 years time (0.9%).
Next Steps
Past Performance
How has Molecular Partners performed over the past 5 years?
-39.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MOLN is currently unprofitable.
Growing Profit Margin: MOLN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MOLN is unprofitable, and losses have increased over the past 5 years at a rate of -39.5% per year.
Accelerating Growth: Unable to compare MOLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MOLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: MOLN has a negative Return on Equity (-67.03%), as it is currently unprofitable.
Next Steps
Financial Health
How is Molecular Partners's financial position?
Financial Position Analysis
Short Term Liabilities: MOLN's short term assets (CHF99.9M) exceed its short term liabilities (CHF28.6M).
Long Term Liabilities: MOLN's short term assets (CHF99.9M) exceed its long term liabilities (CHF22.2M).
Debt to Equity History and Analysis
Debt Level: MOLN is debt free.
Reducing Debt: MOLN has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MOLN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MOLN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Molecular Partners's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MOLN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MOLN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MOLN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MOLN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MOLN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Patrick Amstutz (44yo)
3.5yrs
Tenure
CHF930,000
Compensation
Dr. Patrick Amstutz, Ph.D. is a Co-Founder of Molecular Partners AG and has been its Chief Executive Officer since November 2016 and serves as its Member of Management Board. Dr. Amstutz served as Acting C ...
CEO Compensation Analysis
Compensation vs Market: Patrick's total compensation ($USD961.79K) is about average for companies of similar size in the Swiss market ($USD966.94K).
Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 3.5yrs | CHF930.00k | 3.2% CHF14.8m | |
| Co-Founder | 16.33yrs | no data | 3.47% CHF16.0m | |
| CFO & Member of Management Board | 13.08yrs | no data | 1.1% CHF5.1m | |
| Chief Medical Officer & Member of Management Board | 0.67yr | no data | no data | |
| Vice President of Technology | no data | no data | no data | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| General Counsel | 3.83yrs | no data | no data | |
| Vice President of Human Resources | 1.08yrs | no data | no data | |
| Senior Vice President of Development | 1.08yrs | no data | no data | |
| Senior Vice President of Oncology Research | 1.08yrs | no data | no data |
2.3yrs
Average Tenure
46.5yo
Average Age
Experienced Management: MOLN's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 3.5yrs | CHF930.00k | 3.2% CHF14.8m | |
| Non Executive Director | 6.33yrs | CHF109.00k | 0.018% CHF82.5k | |
| Chairman of the Board | 2.08yrs | CHF327.00k | no data | |
| Director | 3yrs | CHF109.00k | no data | |
| Director | 0.083yr | no data | no data | |
| Director | 0.083yr | no data | no data | |
| Director | 0.083yr | no data | no data |
2.1yrs
Average Tenure
56yo
Average Age
Experienced Board: MOLN's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.3%.
Top Shareholders
Company Information
Molecular Partners AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Molecular Partners AG
- Ticker: MOLN
- Exchange: SWX
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF461.971m
- Shares outstanding: 21.74m
- Website: https://www.molecularpartners.com
Number of Employees
Location
- Molecular Partners AG
- Wagistrasse 14
- Schlieren
- Zurich
- 8952
- Switzerland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MOLN | SWX (SIX Swiss Exchange) | Yes | Registered Shares | CH | CHF | Nov 2014 |
| 0QXX | LSE (London Stock Exchange) | Yes | Registered Shares | GB | CHF | Nov 2014 |
| 6ML | DB (Deutsche Boerse AG) | Yes | Registered Shares | DE | EUR | Nov 2014 |
| MLLC.F | OTCPK (Pink Sheets LLC) | Yes | Registered Shares | US | USD | Nov 2014 |
Biography
Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/05/27 04:58 |
| End of Day Share Price | 2020/05/26 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.